Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Jack Khattar Sells 35,000 Shares

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Jack Khattar sold 35,000 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $50.37, for a total transaction of $1,762,950.00. Following the completion of the sale, the chief executive officer owned 958,100 shares in the company, valued at approximately $48,259,497. This trade represents a 3.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN traded up $0.30 during midday trading on Monday, reaching $50.21. 517,222 shares of the stock were exchanged, compared to its average volume of 762,366. The company has a 50 day simple moving average of $51.22 and a 200 day simple moving average of $49.10. Supernus Pharmaceuticals, Inc. has a twelve month low of $29.16 and a twelve month high of $59.68. The stock has a market capitalization of $2.89 billion, a P/E ratio of -73.84, a PEG ratio of 1.55 and a beta of 0.70.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Stifel Nicolaus raised their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday, December 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Finally, Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Sunday, March 8th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $62.17.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Royal Bank of Canada raised its holdings in Supernus Pharmaceuticals by 68.1% during the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock worth $382,000 after purchasing an additional 4,729 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 35.2% in the 1st quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock valued at $2,791,000 after buying an additional 22,182 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Supernus Pharmaceuticals by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock worth $978,000 after acquiring an additional 1,297 shares during the last quarter. Millennium Management LLC grew its position in shares of Supernus Pharmaceuticals by 370.5% in the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock valued at $4,695,000 after purchasing an additional 112,886 shares during the last quarter. Finally, Empowered Funds LLC raised its stake in Supernus Pharmaceuticals by 16.0% in the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock worth $1,573,000 after purchasing an additional 6,619 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.